Ken Griffin Anavex Life Sciences Corp. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Citadel Advisors LLC holds 266,900 shares of AVXL stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

266,900

Previous 237,500 12.38%

Holding current value

$2.3 Million

Previous $1 Million 51.2%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.11 - $7.04 $1.73 Million - $2.97 Million	-421,313 Reduced 94.29%	25,525 $144,000
Q2 2024 Aug 14, 2024	BUY	$3.39 - $5.02 $1.51 Million - $2.24 Million	446,834 Added 0.0%	446,838 $1.89 Million
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $1.24 Million - $1.84 Million	-273,306 Reduced 100.0%	4 $0
Q4 2023 Feb 14, 2024	SELL	$5.04 - $9.95 $1.52 Million - $3 Million	-301,797 Reduced 52.48%	273,310 $2.54 Million
Q3 2023 Nov 14, 2023	BUY	$6.55 - $9.37 $3.48 Million - $4.98 Million	531,449 Added 1217.3%	575,107 $3.77 Million
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $324,784 - $402,800	42,400 Added 3370.43%	43,658 $354,000
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $1.6 Million - $2.25 Million	-191,781 Reduced 99.35%	1,258 $10,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $2.1 Million - $3.97 Million	-274,867 Reduced 58.74%	193,039 $1.79 Million
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $2.06 Million - $2.98 Million	-231,813 Reduced 33.13%	467,906 $4.83 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $3.44 Million - $6.05 Million	471,144 Added 206.12%	699,719 $7 Million
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $1.9 Million - $3.45 Million	195,197 Added 584.81%	228,575 $2.81 Million
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $562,526 - $776,805	-33,325 Reduced 49.96%	33,378 $578,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $578,170 - $885,130	34,374 Added 106.33%	66,703 $1.2 Million
Q2 2021 Aug 16, 2021	SELL	$10.16 - $28.86 $70,043 - $198,960	-6,894 Reduced 17.58%	32,329 $739,000
Q1 2021 May 17, 2021	SELL	$5.17 - $16.13 $104,232 - $325,196	-20,161 Reduced 33.95%	39,223 $586,000
Q4 2020 Feb 16, 2021	SELL	$4.01 - $7.58 $35,300 - $66,726	-8,803 Reduced 12.91%	59,384 $320,000
Q3 2020 Nov 16, 2020	BUY	$3.8 - $5.0 $204,626 - $269,245	53,849 Added 375.57%	68,187 $310,000
Q2 2020 Aug 14, 2020	SELL	$2.62 - $5.2 $20,661 - $41,007	-7,886 Reduced 35.48%	14,338 $71,000
Q1 2020 May 15, 2020	SELL	$2.38 - $5.81 $133,349 - $325,528	-56,029 Reduced 71.6%	22,224 $70,000
Q4 2019 Feb 14, 2020	BUY	$2.31 - $3.14 $33,176 - $45,096	14,362 Added 22.48%	78,253 $203,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.9 $22,617 - $39,733	-10,188 Reduced 13.75%	63,891 $201,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $123,953 - $166,773	45,074 Added 155.4%	74,079 $249,000
Q1 2019 May 15, 2019	SELL	$1.68 - $3.42 $52,644 - $107,169	-31,336 Reduced 51.93%	29,005 $0
Q4 2018 Feb 14, 2019	SELL	$1.25 - $2.75 $6,278 - $13,813	-5,023 Reduced 7.68%	60,341 $94,000
Q3 2018 Nov 13, 2018	BUY	$2.23 - $3.82 $56,180 - $96,237	25,193 Added 62.71%	65,364 $0
Q2 2018 Aug 10, 2018	BUY	$2.08 - $4.26 $36,491 - $74,737	17,544 Added 77.54%	40,171 $0
Q1 2018 May 11, 2018	BUY	$2.32 - $3.44 $52,494 - $77,836	22,627 New	22,627 $62,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account